Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: FJB who wrote (725576)	7/10/2013 10:30:05 AM
From: joseffy	Respond to of 1578133

Death Of A Drug Class Shows Difficulty Of Using Gene Data To Design Drugs [ Worse under obamacare] Forbes ^ \| 7/10/13 This morning, Roche announced that it was stopping all clinical trials of an experimental diabetes drug called aleglitazar because it was not preventing heart attacks and strokes as the company expected, but was causing side effects that reportedly included heart failure, kidney problems, and an increase in fractures.... (Excerpt) Read more at forbes.com ...